Literature DB >> 23652479

Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.

Adam Frymoyer1, B Joseph Guglielmo, Adam L Hersh.   

Abstract

Vancomycin area under the curve/minimal inhibitory concentration (AUC/MIC) >400 best predicts the outcome when treating invasive methicillin-resistant Staphylococcus aureus infection; however, trough serum concentrations are used clinically to assess the appropriateness of dosing. We used pharmacokinetic modeling and simulation to examine the relationship between vancomycin trough values and AUC/MIC in children receiving vancomycin 15 mg/kg every 6 hours and methicillin-resistant Staphylococcus aureus MIC of 1 μg/mL. A trough of 7-10 μg/mL predicted achievement of AUC/MIC >400 in >90% of children.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23652479     DOI: 10.1097/INF.0b013e318299f75c

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  52 in total

Review 1.  Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis.

Authors:  Geisa Cristina da Silva Alves; Samuel Dutra da Silva; Virginia Paula Frade; Danielle Rodrigues; André de Oliveira Baldoni; Whocely Victor de Castro; Cristina Sanches
Journal:  Eur J Clin Pharmacol       Date:  2017-08-04       Impact factor: 2.953

2.  Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?

Authors:  Karisma Patel; Ashley S Crumby; Holly D Maples
Journal:  Paediatr Drugs       Date:  2015-04       Impact factor: 3.022

3.  Are vancomycin trough concentrations adequate for optimal dosing?

Authors:  Michael N Neely; Gilmer Youn; Brenda Jones; Roger W Jelliffe; George L Drusano; Keith A Rodvold; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

4.  Vancomycin monitoring in children using bayesian estimation.

Authors:  Jennifer Le; Becky Ngu; John S Bradley; William Murray; Austin Nguyen; Lyn Nguyen; Gale L Romanowski; Tiana Vo; Edmund V Capparelli
Journal:  Ther Drug Monit       Date:  2014-08       Impact factor: 3.681

5.  Pediatric vancomycin dosing: Trends over time and the impact of therapeutic drug monitoring.

Authors:  Alfred H Balch; Jonathan E Constance; Emily A Thorell; Chris Stockmann; Ernest K Korgenski; Sarah C Campbell; Michael G Spigarelli; Catherine M T Sherwin
Journal:  J Clin Pharmacol       Date:  2014-11-07       Impact factor: 3.126

6.  Lower vancomycin serum trough concentrations might not be the answer.

Authors:  Andrea Hahn; Alexander A Vinks
Journal:  Pediatr Infect Dis J       Date:  2013-12       Impact factor: 2.129

7.  Anti-infective use in children and pregnancy: current deficiencies and future challenges.

Authors:  Amanda Gwee; Noel Cranswick
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

8.  Use of Individual Pharmacokinetics to Improve Time to Therapeutic Vancomycin Trough in Pediatric Oncology Patients.

Authors:  Calvin L Miller; S Alexander Winans; John J Veillette; Steven C Forland
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

9.  Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.

Authors:  Rana F Hamdy; Alice J Hsu; Chris Stockmann; Jared A Olson; Matthew Bryan; Adam L Hersh; Pranita D Tamma; Jeffrey S Gerber
Journal:  Pediatrics       Date:  2017-05-05       Impact factor: 7.124

10.  Evaluation of Vancomycin Dosing in Pediatric Cystic Fibrosis Patients.

Authors:  Erin J McDade; Jennifer L Hewlett; Siby P Moonnumakal; Carol J Baker
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.